Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY3074828 in moderate to severe ulcerative colitis
NL-OMON46940Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mirikizumab in autoimmune colitis and inflammatory bowel disease (IBD) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Clinical remission at Week 12. Started Jun 2016; status: active, not recruiting.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON46940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46940.